~~<i id='1A615AA13D'><strike id='1A615AA13D'><tt id='1A615AA13D'><pre id='1A615AA13D'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

WSS

Notifications
- knowledge
23andMe had bad news about my health. I wish a person had delivered it
log on

entertainment

explore

author：fashion 2025-09-02 22:07:43 - browse：255

Sanofi will license a new CRISPR enzyme from the startup Scribe Therapeutics in a bid to be the first to develop a safer, simpler, and more scalable cure for sickle cell disease.

The French drugmaker will pay Scribe $40 million upfront and promise another $1.2 billion in potential milestones to license a DNA-cutting enzyme called CasX for use in a potential single-infusion treatment for the serious blood disorder — what’s known as in vivo therapy.CasX was discovered in CRISPR pioneer Jennifer Doudna’s lab, which subsequently spun out Scribe.

Scribe was planning to announce the news Tuesday, but it was published early Monday by GEN.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： With clinical trial data readouts, here's how to spot spin

explore

knowledge

focus

Hevolution'sexecutiveteamincludes,fromleft,SophiaPathai,HayaBintKhaledBinBandarAlSaud,MehmoodKhan,an

WSS

The untold story of TV’s first prescription drug ad

Families look for replacement for GSK asthma drug Flovent

$1 billion proposal to grow Boston, Massachusetts biotech

How to pay for weight loss drugs and save Medicare

BIO selects John Crowley as new CEO

Biden's 'march

entertainment

explore

explore

New air purifier tech could be key to improving indoor air quality

Flagship Pioneering launches a new biotech in two countries

What does generative AI mean for health care? We asked experts

Medicare drug price negotiation hearing pits pharma v Biden admin

What does generative AI mean for health care? We asked experts

Disappointing trial forces Pfizer to pivot on obesity medicine plans

Drug repurposing or repositioning? The language matters

The untold story of TV’s first prescription drug ad

Activists slam private health insurers over coverage restrictions

Organ aging and disease risk measured by new blood test

explore

State of the Union pitch: Bigger Medicare drug price negotiations

Fetal cell organoids grown from amniotic fluid, study finds

Immune cells and nerve overgrowth may explain recurring UTI pain

As biotech industry slumps, bioscience job market is upside down

The public health thinking behind the CDC’s new Covid guidance

With clinical trial data readouts, here's how to spot spin

knowledge

focus

focus

focus